| A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1) |
Completed |
A4250-005 |
3 |
A4250-005 |
KFSH&RC-R |
| A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer |
Completed |
Sorafenib |
3 |
BAY43-9006/14295 |
KFSH & RC-R |
| A Compartive Multicenter Study of Neoadjuvant Docetaxel/Cisplatin Followed by Concurrent Cisplatin with Radiotherapy using Intensity-Modulated Radition Therapy (IMRT) with or without Bevacizumab for Locally Advanced Nasopharyngeal Cancer |
Completed |
Docetaxel/Cisplatin and Bevacizumab |
3 |
Version 1.3 date 6 may 2012 |
KFMC |
| A 96-week, two-arm, randomized, single-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (CONDOR) |
Completed |
Brolucizumab |
3 |
CRTH258D2301 |
DESH |
| A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation |
Completed |
paliperidone |
3 |
R092670SCH3015 |
JPH |
| A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed' |
Completed |
Budesonide + Formoterol VS. Budesonide + Terbutaline |
3 |
D589SC00003 |
AFH-DH |
| A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients |
Completed |
Travoprost 0.004% / Timolol |
3 |
C-12-008 |
KKESH |
| A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma |
Terminated |
QAW039/Fevipiprant |
3 |
CQAW039A2315 |
KFMC |
| A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma |
Terminated |
QAW039/Fevipiprant |
3 |
CQAW039A2315 |
KFMC |
| A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants |
Completed |
Everolimus + reduced tacrolimus VS.Tacrolimus |
3 |
CRAD001H2307 |
KFSH & RC-R |
